Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?
ContributorsZaidi, Habib
Published inEuropean journal of nuclear medicine and molecular imaging, vol. 35, no. 7, p. 1330-1333
Collection
- Open Access - Licence nationale Springer
Publication date2008
Keywords
- Brain/physiology/radionuclide imaging
- Caudate Nucleus/physiopathology/radionuclide imaging
- Dopamine/physiology
- Dopamine Plasma Membrane Transport Proteins/physiology
- Humans
- Iodine Radioisotopes/diagnostic use
- Ligands
- Movement Disorders/physiopathology/radionuclide imaging
- Putamen/physiopathology/radionuclide imaging
- Radiopharmaceuticals/diagnostic use
- Synaptic Transmission/physiology
- Tomography, Emission-Computed, Single-Photon/methods
NoteComment on: Crespo C, Gallego J, Cot A, Falcón C, Bullich S, Pareto D, Aguiar P, Sempau J, Lomeña F, Calviño F, Pavía J, Ros D. Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1334-42.
Research group
Citation (ISO format)
ZAIDI, Habib, EL FAKHRI, Georges. Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use? In: European journal of nuclear medicine and molecular imaging, 2008, vol. 35, n° 7, p. 1330–1333. doi: 10.1007/s00259-008-0842-x
Main files (1)
Article (Published version)
Identifiers
- PID : unige:2457
- DOI : 10.1007/s00259-008-0842-x
- PMID : 18523768
ISSN of the journal1619-7070
